banner
  HOME | CDC SCHEDULE 

NOTE:
The NJIIS recommendations are based on the current ACIP, AAP and AAFP schedule for routine well child immunization. The recommended schedule of immunizations for children who are immuno-compromised or have other serious medical conditions is not included in this system.

 

 

 

USERNAME

PASSWORD
 

Forgot Password

Session Expired !

BULLETIN BOARD

Updated 06-21-2017 - Please scroll to read the entire message

  • 6/21/2017 Effective immediately, GSK has stopped producing new lots of MenHibrix. Menhibrix is no longer available from the VFC program. Menhibrix supplied by VFC will expire on September 17, 2017, or earlier. Return all expired vaccine by obtaining a pre-paid Waste Return Label in IMODS or NJIIS.

  • 6/20/2017 Updated MMWR Recommendations Regarding the Use of MenB-FHbp vaccine (TrumenbaŽ). These recommendations are regarding use of the 2- dose (administered at 0 and 6 months) and 3-dose schedules of MenB-FHbp vaccine and replace previous ACIP recommendations for use of MenB-FHbp vaccine published in 2015. Recommendations regarding use of MenB-4C (BexseroŽ) are unchanged. Click Here for the updated Trumenba recommendation in the MMWR. Click Here for full Trumenba prescribing information.

  • 5/2/2017 Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine), Sanofi Pasteur's DTaP-IPV combination vaccine, will be available to order in May. Quadracel is the second DTaP-IPV vaccine to be licensed for use among children aged 4 through 6 years in the United States. Quadracel is approved for administration as a fifth dose in the DTaP series and as a fourth or fifth dose in the IPV series in children aged 4 through 6 years who have received 4 doses of DTaP-IPV-Hib (Pentacel) and/or DTaP (Daptacel) vaccine. For more information, read the MMWR's Guidance for Use of Quadracel Here. Full prescribing information can be read Here.

  • 02/10/2017 ACIP APPROVES 2-DOSE HPV IMMUNIZATION FOR ADOLESCENTS 11-14 YEARS OF AGE - It is recommended that 9 through 14 year olds receive two doses of HPV vaccine at least six months apart, rather than three doses. Young adults aged 15 through 26 years will continue to need three doses of HPV vaccine at 0, 2, & 6 months. For more information, read the CDC's MMWR Here

  • 01/20/2017- The New Jersey VFC Program would like to share a QUICK GUIDE as a reminder of how to enter vaccine administration data into NJIIS after revaccinating a patient. Should you have further questions about entering vaccine administration data into NJIIS, please contact your NJIIS Trainer by SUBMITTING AN ONLINE INQUIRY.


  • THE CDC HAS CHANGED THE MINIMUM TEMPERATURE TO STORE REFRIGERATED VACCINE FROM 35F to 36F, click here for more information. Click hereto view the Vaccine Storage and Handling Toolkit.